125 332

Cited 31 times in

Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial

 Jin Won Kim  ;  Sae Won Han  ;  Jae Yong Cho  ;  Ik-Joo Chung  ;  Jong Gwang Kim  ;  Kyung Hee Lee  ;  Keon Uk Park  ;  Sun Kyung Baek  ;  Sang Cheul Oh  ;  Myung Ah Lee  ;  Doyeun Oh  ;  Byoungyong Shim  ;  Joong Bae Ahn  ;  Dongbok Shin  ;  Jae Won Lee  ;  Yeul Hong Kim 
 EUROPEAN JOURNAL OF CANCER, Vol.130 : 51-62, 2020-05 
Journal Title
Issue Date
Colorectal Neoplasms / complications ; Colorectal Neoplasms / drug therapy* ; Double-Blind Method ; Fatigue / drug therapy* ; Female ; Humans ; Male ; Middle Aged ; Panax / chemistry* ; Prognosis ; Quality of Life / psychology*
Cancer-related fatigue ; Korean red ginseng ; mFOLFOX-6 ; Colorectal canoe
Background: Cancer-related fatigue (CRF) is a common symptom and has a negative impact on prognosis in cancer patients. CRF could be improved by Korean red ginseng (KRG). Patients and methods: For this randomised and double-blinded trial, colorectal cancer patients who received mFOLFOX-6 were randomly assigned to either KRG 2000 mg/day (n = 219) or placebo (n = 219) for 16 weeks. CRF was evaluated using the mean area under the curve (AUC) change from baseline of brief fatigue inventory (BFI) as the primary endpoint. Fatigue-related quality of life, stress, and adverse events were evaluated as secondary endpoints. Results: In the full analysis group, KRG up to 16 weeks improved CRF by the mean AUC change from baseline of BFI compared to placebo, particularly in "Mood" and "Walking ability" (P = 0.038, P = 0.023, respectively). In the per-protocol group, KRG led to improved CRF in the global BFI score compared with the placebo (P = 0.019). Specifically, there were improvements in "Fatigue right now," "Mood," "Relations with others," "Walking ability," and "Enjoyment of life" at 16 weeks (P = 0.045, P = 0.006, P = 0.028, P = 0.003, P = 0.036, respectively). In subgroups of female patients, >60 years old, with high compliance (>80%) or more baseline fatigue, the beneficial effects of KRG were more enhanced than that of placebo. Although neutropenia was more frequent in KRG than placebo, the incidence of all adverse events was similar. Conclusions: KRG could be safely combined with mFOLFOX-6 chemotherapy in colorectal cancer patients, and reduced CRF compared with placebo.
Files in This Item:
T9992020346.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
Cho, Jae Yong(조재용) ORCID logo https://orcid.org/0000-0002-0926-1819
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.